• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AstraZeneca Has a Promising Oncology Pipeline

Article

AstraZeneca's Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

AstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

In oncology, olaparib for solid tumours, moxetumomab pasudotox for hairy cell leukaemia and selumetinib for non-small cell lung cancer are expected to be key players. Also showing potential are AZD9291 a ‘third generation’ tyrosine kinase inhibitor for NSCLC, and from AstraZeneca’s biologics R&D arm MedImmune, MEDI4736, a PD-L1 monoclonal antibody that is being studied in patients with advanced solid tumours.

Within AZ’s oncology franchise, the breast cancer portfolio has been targeted for expansion and a raft of new combination therapies is under investigation,. However substantial growth is expected from established agents such as Faslodex (fulvestrant).

Read the full story at:

http://bit.ly/P1u39eSource: PharmaTimes

Related Videos
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Emily Touloukian, DO, Coastal Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.